Jacques S. Lapointe

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients.

A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients.

Journal: British journal of cancer

Published: November 23, 2022

Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.

Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.

Journal: Oncogene

Published: April 16, 2021

CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis.

CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis.

Journal: Communications biology

Published: November 20, 2020

Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples.

Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples.

Journal: The Journal of molecular diagnostics : JMD

Published: February 14, 2020

A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.

A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.

Journal: The Prostate

Published: March 04, 2019

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer.

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer.

Journal: Cancer cell international

Published: September 27, 2018

The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.

The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: March 27, 2018

Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention.

Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention.

Journal: Molecular cancer research : MCR

Published: May 17, 2017

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Journal: Genes & development

Published: April 03, 2017

Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores.

Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores.

Journal: PloS one

Published: October 24, 2016

Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction.

Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction.

Journal: Journal of visualized experiments : JoVE

Published: September 02, 2016

Inhibition of Helicobacter pylori Glu-tRNAGln amidotransferase by novel analogues of the putative transamidation intermediate.

Inhibition of Helicobacter pylori Glu-tRNAGln amidotransferase by novel analogues of the putative transamidation intermediate.

Journal: FEBS letters

Published: June 30, 2016

Showing 1-12 of 21

Last Updated: 09/26/2026